Back to Journals » Clinical Interventions in Aging » Volume 6

Rehabilitating a brain with Alzheimer's: a proposal

Authors Aranda-Abreu GE, Hernandez ME, Manzo J, Garcia LI, Marisol Herrera Rivero

Published 22 February 2011 Volume 2011:6 Pages 53—59

DOI https://doi.org/10.2147/CIA.S14008

Review by Single-blind

Peer reviewer comments 2


Gonzalo Emiliano Aranda-Abreu1,3, María Elena Hernández-Aguilar1,3, Jorge Manzo Denes1,4, Luis Isauro García Hernández1,4, Marisol Herrera Rivero2
1
Programa de Neurobiología, 2Doctorado en Ciencias Biomédicas, Universidad Veracruzana, Xalapa, Veracruz, México, 3Cuerpo Académico de Neuroquímica, 4Cuerpo Académico de Neurociencias.
Abstract: Alzheimer's disease (AD) is the most common neurodegenerative disorder, originating sporadically in the population aged over 65 years, and advanced age is the principal risk factor leading to AD development. In spite of the large amount of research going on around the globe and all the information now available about AD, there is still no origin or triggering process known so far. Drugs approved for the treatment of AD include tacrine, donepezil, rivastigmine, galantamine, and memantine. These may delay or slow down the degenerative process for a while, but they can neither stop nor reverse its progression. Because that this might be due to a lack of effect of these drugs on degenerating neurons, even when they are able to potentiate the brain in nondegenerative conditions, we propose here an alternative therapy consisting of initial repair of neuronal membranes followed by conventional drug therapies. The rehabilitation of neurons in a degeneration process would enable the drugs to act more effectively on them and improve the effects of treatment in AD patients.

Keywords: Alzheimer, Rehabilitation, Drugs

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]